DBV Technologies SA banner

DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 3.395 EUR -0.15% Market Closed
Market Cap: €945m

DBV Technologies SA
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

DBV Technologies SA
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
DBV Technologies SA
PAR:DBV
Other
-$345k
CAGR 3-Years
8%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other
-€19m
CAGR 3-Years
-27%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other
-€7.9m
CAGR 3-Years
-57%
CAGR 5-Years
0%
CAGR 10-Years
-58%
Inventiva SA
PAR:IVA
Other
€129m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abivax SA
PAR:ABVX
Other
-€12.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sensorion SA
PAR:ALSEN
Other
-€4.1m
CAGR 3-Years
-125%
CAGR 5-Years
-104%
CAGR 10-Years
N/A
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
945m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
1.095 EUR
Overvaluation 68%
Intrinsic Value
Price

See Also

What is DBV Technologies SA's Other?
Other
-345k USD

Based on the financial report for Jun 30, 2025, DBV Technologies SA's Other amounts to -345k USD.

What is DBV Technologies SA's Other growth rate?
Other CAGR 5Y
23%

Over the last year, the Other growth was -53%. The average annual Other growth rates for DBV Technologies SA have been 8% over the past three years , 23% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett